Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:HOTHNASDAQ:KERNNASDAQ:MEDS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeHOTHHoth Therapeutics$0.93-2.5%$0.93$0.58▼$3.80$12.24M0.533.47 million shs1.20 million shsKERNAkerna$5.89$0.17▼$6.40$64.92M3.02339,022 shs70,795 shsMEDSTRxADE HEALTH$0.92-1.6%$1.22$3.69▼$44.56$1.29M2.32207,831 shs70,297 shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceHOTHHoth Therapeutics-2.47%+6.95%+16.02%-8.91%-20.60%KERNAkerna0.00%0.00%0.00%0.00%0.00%MEDSTRxADE HEALTH0.00%-3.26%+12.61%-71.87%-84.03%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationHOTHHoth Therapeutics3.2796 of 5 stars3.65.00.00.02.50.81.3KERNAkernaN/AN/AN/AN/AN/AN/AN/AN/AMEDSTRxADE HEALTHN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceHOTHHoth Therapeutics 3.25Buy$4.00330.52% UpsideKERNAkerna 0.00N/AN/AN/AMEDSTRxADE HEALTH 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest KERN, MEDS, and HOTH Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/15/2025HOTHHoth TherapeuticsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.00 ➝ $5.003/31/2025HOTHHoth TherapeuticsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.00 ➝ $5.003/10/2025HOTHHoth TherapeuticsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.00 ➝ $5.003/4/2025HOTHHoth TherapeuticsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.00 ➝ $5.00(Data available from 5/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookHOTHHoth TherapeuticsN/AN/AN/AN/A$2.03 per shareN/AKERNAkerna$13.65M0.00N/AN/A($1.52) per share0.00MEDSTRxADE HEALTH$7.45M0.17N/AN/A$0.45 per share2.04Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateHOTHHoth Therapeutics-$7.84M-$1.33N/AN/AN/AN/A-89.68%-82.61%5/13/2025 (Estimated)KERNAkerna-$79.06M-$7.10N/AN/AN/A-339.99%N/A-113.03%N/AMEDSTRxADE HEALTH-$17.84MN/A0.00∞N/A-149.81%-196.79%-112.21%6/24/2025 (Estimated)Latest KERN, MEDS, and HOTH EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2025Q1 2025HOTHHoth Therapeutics-$0.34-$0.27+$0.07-$0.27N/AN/A3/27/2025Q4 2024HOTHHoth Therapeutics-$0.39-$0.32+$0.07-$0.32N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthHOTHHoth TherapeuticsN/AN/AN/AN/AN/AKERNAkernaN/AN/AN/AN/AN/AMEDSTRxADE HEALTHN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioHOTHHoth TherapeuticsN/A10.1710.17KERNAkernaN/A0.100.10MEDSTRxADE HEALTHN/A4.184.18Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipHOTHHoth Therapeutics7.08%KERNAkerna21.97%MEDSTRxADE HEALTH5.68%Insider OwnershipCompanyInsider OwnershipHOTHHoth Therapeutics10.56%KERNAkerna1.20%MEDSTRxADE HEALTH48.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableHOTHHoth Therapeutics413.17 million6.18 millionNot OptionableKERNAkerna11210.35 million10.23 millionNo DataMEDSTRxADE HEALTH501.41 million725,000Not OptionableKERN, MEDS, and HOTH HeadlinesRecent News About These CompaniesOragenics gears up for Phase II trials, appoints new CEOJanuary 21, 2025 | msn.comTRxADE Health (NASDAQ: MEDS)November 23, 2024 | fool.comScienture Holdings, Inc. (SCNX)November 15, 2024 | finance.yahoo.comTravis County extends opioid public health crisis declarationNovember 13, 2024 | msn.comMedicaid covers GLP-1 meds for obesity in just 13 states, analysis findsNovember 5, 2024 | medicalxpress.comYou Can Now Get Prescription Weight Loss Drugs Like Ozempic From An Online Telehealth Visit. But Is It Safe?November 5, 2024 | msn.comADHD drugs' impact on brain health, quality of life: What we knowOctober 31, 2024 | medicalnewstoday.comUS releases preliminary list of $2 generic drugs for Medicare recipientsOctober 11, 2024 | reuters.comMedications increase risk for heat-related illnesses during extended heat waveOctober 11, 2024 | msn.comHarvard Health Ad Watch: Got side effects? There's a medicine for thatOctober 11, 2024 | msn.comCMS releases RFI, sample list of prescription drugs that may be included under proposed Medicare $2 Drug List ModelOctober 11, 2024 | aha.orgThe end of a shortage of popular weight-loss drugs may mean many people lose access to themOctober 11, 2024 | msn.comWeight-loss drugs are life-changing — and expensive. Here's one woman's solution.September 27, 2024 | aol.comOlder migraine drugs more effective than some newer options, study findsSeptember 25, 2024 | medicalnewstoday.comGoogle trends reveals surge in ADHD medication searches during COVID-19 pandemicSeptember 24, 2024 | medicalxpress.comTRxADE Health, Inc. Announces Name Change to Scienture Holdings, Inc. and Ticker Symbol Change to “SCNX”September 24, 2024 | markets.businessinsider.comScienture Holdings Inc (SCNX)September 24, 2024 | sg.finance.yahoo.comTriptans better at relieving migraine pain than recently marketed and more expensive drugsSeptember 23, 2024 | news-medical.netTypes of Medications for Heart Attack Prevention and TreatmentSeptember 21, 2024 | verywellhealth.comInside the thriving market for alternatives to brand-name weight loss drugsSeptember 21, 2024 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeKERN, MEDS, and HOTH Company DescriptionsHoth Therapeutics NASDAQ:HOTH$0.93 -0.02 (-2.47%) Closing price 05/12/2025 04:00 PM EasternExtended Trading$0.92 -0.01 (-0.98%) As of 08:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Hoth Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs. It is involved in the development of HT-001, a topical formulation, which is in Phase II clinical trial for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to treat mast-cell derived cancers and anaphylaxis; HT-TBI to treat traumatic brain injury and ischemic stroke; HT-ALZ for the treatment and/or prevention of Alzheimer's or other neuroinflammatory diseases; HT-004 for treatment of asthma and allergies using inhalational administration; HT-003 for the treatment of acne and psoriasis, as well as inflammatory bowel diseases; and HT-002, a novel peptide for treating COVID-19. The company is also developing BioLexa Platform, a proprietary, patented, drug compound platform which is in Phase I clinical trial for the treatment of eczema; and HT-005 for treating patients with lupus, as well as a diagnostic device through a mobile device. The company has license agreements with the George Washington University; Isoprene Pharmaceuticals, Inc.; Virginia Commonwealth University; the North Carolina State University; Chelexa BioSciences, Inc. and the University of Cincinnati; Zylö Therapeutics, Inc.; and Voltron Therapeutics, Inc. It also has a research collaboration agreement with Weill Cornell Medicine to develop HT-003. Hoth Therapeutics, Inc. was incorporated in 2017 and is based in New York, New York.Akerna NASDAQ:KERNAkerna Corp. provides enterprise software solutions that enable regulatory compliance and inventory management in the United States and Canada. The company offers MJ Platform for the cannabis, hemp, and CBD industry; and Leaf Data Systems, a government regulatory software. It also provides consulting services to cannabis industry; business intelligence, data analytics and other software related services; and Last Call Analytics, a retail analytics platform. In addition, the company operates Solo, a seed-to-sale tagging and tracking software platform, and Trellis, a cultivation and compliance software platform. Akerna Corp. was founded in 2010 and is headquartered in Denver, Colorado.TRxADE HEALTH NASDAQ:MEDS$0.92 -0.02 (-1.60%) As of 05/9/2025TRxADE HEALTH, Inc. operates as a health services information technology (IT) company in the United States. The company focuses on digitalizing the retail pharmacy experience by optimizing drug procurement, prescription journey, and patient engagement; and designs, develops, owns, and operates a business-to-business web-based marketplace. It also distributes prescription medication, medical devices, and over the counter medication to pharmacies and medical clinics; and offers pricing transparency, purchasing capabilities, and other value-added services, as well as telehealth services. The company was formerly known as Trxade Group, Inc. and changed its name to TRxADE HEALTH, Inc. in June 2021. TRxADE HEALTH, Inc. was founded in 2010 and is headquartered in Lutz, Florida. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Palantir’s Latest Deal Could Put a Freeze on Its Stock Price A 90-Day Tariff Pause Sends Alibaba Flying—BlackRock Was Ready Why DraftKings Share Price Could Soar to Multi-Year Highs BP Buyout Buzz Puts Spotlight on Transocean’s Comeback Potential Here's Why Call Option Traders Love Dutch Bros Stock Can Shopify Stock Make a Comeback After an Earnings Sell-Off? MarketBeat Week in Review – 05/05 - 05/09 Taiwan Semiconductor Has a New Reason to Rally on Chip Curbs Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
